Molecular Monitoring Advances in PV Disease Assessment and Management
A panelist discusses how advances in JAK2 V617F and other molecular monitoring have enhanced their ability to assess polycythemia vera (PV) disease progression and guide initial treatment decisions by providing quantifiable markers for tracking mutation burden, treatment response, and risk stratification that complement traditional clinical parameters.
Video content above is prompted by the following:
- Please explain how advances in JAK2 V617Fand other molecular monitoring have enhanced your ability to assess disease progression and guide initial treatment decisions for your patients with PV.
Ruxolitinib Effective as Second-Line Therapy for Chronic GvHD
July 15th 2021In an interview with Targeted Oncology, Stephanie Lee, MD, MPH, reviewed the updated data from the REACH3 trial along with the efficacy of ruxolitinib in the greater chronic graft versus host disease population.
Read More
Clinical Treatment Act Aims to Improve Survival, Close Racial Health Care Gap
June 28th 2021Across the United States, the health insurance coverage gap continues to impact millions of patients who are largely low-income or are racial minorities. After years of lobbying, Congress has passed the Clinical Treatment Act, which is legislation designed to improve access to health coverage.
Read More
